Notch Therapeutics
Notch has developed a next-generation approach to producing uniform, stem cell-derived, gene-edited immune cell therapies on a large scale by mimicking the “niche” of the human thymus, where T cells originate. At the core of Notch’s technology, the proprietary Engineered Thymic Niche (ETN) platform enables the expansion and differentiation of induced pluripotent stem cells (iPSCs) in fully defined, feeder-free, and serum-free cultures into mature T cells and other types of immune cells that can be scaled up to create cell banks for thousands of patients. A key feature of our technology is that the immune cells can be uniformly gene-edited at the stem cell stage for any immune cell-based therapeutic application, including CARs, CRISPR, and synthetic biology. The Notch ETN technology was invented by Juan-Carlos Zúñiga-Pflücker, PhD at Sunnybrook Research Institute and Peter Zandstra, PhD, FRSC at the University of Toronto.
